Provider : Wright Reports
Bavarian Nordic A/S: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider : Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Bavarian Nordic A/S Receives Health Canada Approval of IMVAMUNE Smallpox Vaccine
Bavarian Nordic A/S announced that Health Canada has granted a Notice of Compliance approving IMVAMUNE for active immunization against smallpox in a public health emergency. IMVAMUNE is indicated for persons 18 years of age and older who are contraindicated to replicating smallpox vaccines. This includes individuals with immune deficiencies and skin disorders. Health Canada is the second regulatory body to approve the Company's smallpox vaccine which earlier this year was approved by the European Commission for use in the general adult population in all 28 EU countries and Iceland, Liechtenstein and Norway, where it is marketed under the trade name IMVANEX.
Latest Developments forBavarian Nordic A/S
Latest Key Developments inPharmaceuticals
- AB Science says unblinding of phase 3 mastocytosis study data planned for November
- Mirna Therapeutics, Inc announces closing of initial public offering and concurrent private placement with CPRIT
- U.S. FDA grants priority review for Bristol-Myers Squibb's daklinza (daclatasvir) sndas
- Eagle Pharmaceuticals completes clinical treatment portion of its safety and efficacy study of ryanodex for exertional heat stroke
- Share this
- Digg this